158 related articles for article (PubMed ID: 24140051)
1. A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains.
Doyle TM; Li C; Bucher DJ; Hashem AM; Van Domselaar G; Wang J; Farnsworth A; She YM; Cyr T; He R; Brown EG; Hurt AC; Li X
Biochem Biophys Res Commun; 2013 Nov; 441(1):226-9. PubMed ID: 24140051
[TBL] [Abstract][Full Text] [Related]
2. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes.
Doyle TM; Hashem AM; Li C; Van Domselaar G; Larocque L; Wang J; Smith D; Cyr T; Farnsworth A; He R; Hurt AC; Brown EG; Li X
Antiviral Res; 2013 Nov; 100(2):567-74. PubMed ID: 24091204
[TBL] [Abstract][Full Text] [Related]
3. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences.
Gravel C; Li C; Wang J; Hashem AM; Jaentschke B; Xu KW; Lorbetskie B; Gingras G; Aubin Y; Van Domselaar G; Girard M; He R; Li X
Vaccine; 2010 Aug; 28(36):5774-84. PubMed ID: 20621113
[TBL] [Abstract][Full Text] [Related]
4. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
[TBL] [Abstract][Full Text] [Related]
5. Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility.
Farrukee R; Leang SK; Butler J; Lee RT; Maurer-Stroh S; Tilmanis D; Sullivan S; Mosse J; Barr IG; Hurt AC
J Antimicrob Chemother; 2015 Jul; 70(7):2004-12. PubMed ID: 25786478
[TBL] [Abstract][Full Text] [Related]
6. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses.
Shen C; Chen J; Li R; Zhang M; Wang G; Stegalkina S; Zhang L; Chen J; Cao J; Bi X; Anderson SF; Alefantis T; Zhang M; Cai X; Yang K; Zheng Q; Fang M; Yu H; Luo W; Zheng Z; Yuan Q; Zhang J; Wai-Kuo Shih J; Kleanthous H; Chen H; Chen Y; Xia N
Sci Transl Med; 2017 Oct; 9(412):. PubMed ID: 29046433
[TBL] [Abstract][Full Text] [Related]
7. Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.
Wohlbold TJ; Podolsky KA; Chromikova V; Kirkpatrick E; Falconieri V; Meade P; Amanat F; Tan J; tenOever BR; Tan GS; Subramaniam S; Palese P; Krammer F
Nat Microbiol; 2017 Oct; 2(10):1415-1424. PubMed ID: 28827718
[TBL] [Abstract][Full Text] [Related]
8. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.
Wilson JR; Guo Z; Reber A; Kamal RP; Music N; Gansebom S; Bai Y; Levine M; Carney P; Tzeng WP; Stevens J; York IA
Antiviral Res; 2016 Nov; 135():48-55. PubMed ID: 27713074
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.
Wan H; Qi L; Gao J; Couzens LK; Jiang L; Gao Y; Sheng ZM; Fong S; Hahn M; Khurana S; Taubenberger JK; Eichelberger MC
J Virol; 2018 Feb; 92(4):. PubMed ID: 29167344
[TBL] [Abstract][Full Text] [Related]
10. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations.
Jackson D; Barclay W; Zürcher T
J Antimicrob Chemother; 2005 Feb; 55(2):162-9. PubMed ID: 15665027
[TBL] [Abstract][Full Text] [Related]
11. Reverse engineering the antigenic architecture of the haemagglutinin from influenza H5N1 clade 1 and 2.2 viruses with fine epitope mapping using monoclonal antibodies.
Rockman S; Camuglia S; Vandenberg K; Ong C; Baker MA; Nation RL; Li J; Velkov T
Mol Immunol; 2013 Apr; 53(4):435-42. PubMed ID: 23127859
[TBL] [Abstract][Full Text] [Related]
12. Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective.
Madsen A; Dai YN; McMahon M; Schmitz AJ; Turner JS; Tan J; Lei T; Alsoussi WB; Strohmeier S; Amor M; Mohammed BM; Mudd PA; Simon V; Cox RJ; Fremont DH; Krammer F; Ellebedy AH
Immunity; 2020 Oct; 53(4):852-863.e7. PubMed ID: 32976769
[TBL] [Abstract][Full Text] [Related]
13. Surveillance and molecular characterization of human influenza B viruses during 2006-2010 revealed co-circulation of Yamagata-like and Victoria-like strains in eastern India.
Roy T; Agrawal AS; Mukherjee A; Mishra AC; Chadha MS; Kaur H; Chawla-Sarkar M
Infect Genet Evol; 2011 Oct; 11(7):1595-601. PubMed ID: 21708292
[TBL] [Abstract][Full Text] [Related]
14. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
Wang D; Sleeman K; Huang W; Nguyen HT; Levine M; Cheng Y; Li X; Tan M; Xing X; Xu X; Klimov AI; Gubareva LV; Shu Y
Antiviral Res; 2013 Mar; 97(3):240-4. PubMed ID: 23267831
[TBL] [Abstract][Full Text] [Related]
15. Development of A4 antibody for detection of neuraminidase I223R/H275Y-associated antiviral multidrug-resistant influenza virus.
Guk K; Kim H; Lee M; Choi YA; Hwang SG; Han G; Kim HN; Kim H; Park H; Yong D; Kang T; Lim EK; Jung J
Nat Commun; 2020 Jul; 11(1):3418. PubMed ID: 32647286
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a fully human monoclonal antibody against extracellular domain of matrix protein 2 of influenza A virus.
Ozawa T; Jin A; Tajiri K; Takemoto M; Okuda T; Shiraki K; Kishi H; Muraguchi A
Antiviral Res; 2011 Sep; 91(3):283-7. PubMed ID: 21726583
[TBL] [Abstract][Full Text] [Related]
17. A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.
Momont C; Dang HV; Zatta F; Hauser K; Wang C; di Iulio J; Minola A; Czudnochowski N; De Marco A; Branch K; Donermeyer D; Vyas S; Chen A; Ferri E; Guarino B; Powell AE; Spreafico R; Yim SS; Balce DR; Bartha I; Meury M; Croll TI; Belnap DM; Schmid MA; Schaiff WT; Miller JL; Cameroni E; Telenti A; Virgin HW; Rosen LE; Purcell LA; Lanzavecchia A; Snell G; Corti D; Pizzuto MS
Nature; 2023 Jun; 618(7965):590-597. PubMed ID: 37258672
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
Gubareva LV
Virus Res; 2004 Jul; 103(1-2):199-203. PubMed ID: 15163510
[TBL] [Abstract][Full Text] [Related]
19. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus.
Hashem AM; Van Domselaar G; Li C; Wang J; She YM; Cyr TD; Sui J; He R; Marasco WA; Li X
Biochem Biophys Res Commun; 2010 Dec; 403(2):247-51. PubMed ID: 21078301
[TBL] [Abstract][Full Text] [Related]
20. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
